AROMASIN® Tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator.
AROMASIN Tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Media Articles Related to Aromasin (Exemestane)
Exemestane Well-Tolerated for Breast Cancer Prevention
Source: Medscape Medical News Headlines [2014.04.18]
When given to prevent breast cancer in postmenopausal women, the aromatase inhibitor exemestane has little effect on quality of life, according to follow-up results of the MAP.3 trial.
Reuters Health Information
First genetic link discovered to difficult-to-diagnose breast cancer sub-type
Source: Breast Cancer News From Medical News Today [2014.04.17]
Scientists have identified the first genetic variant specifically associated with the risk of a difficult-to-diagnose cancer sub-type accounting for around 10-15 per cent of all breast cancer cases.
New blood test 'accurately predicts breast cancer recurrence'
Source: Blood / Hematology News From Medical News Today [2014.04.15]
Researchers have developed a blood test that they say predicts breast cancer recurrence with up to 95% accuracy and effectively monitors patients' response to chemotherapy.
ZMYND11 'reads' methylated variant to thwart cancer; tied to breast cancer patient survival
Source: Breast Cancer News From Medical News Today [2014.04.15]
A tumor-suppressing protein acts as a dimmer switch to dial down gene expression.
Lung Cancer: A Dose-Dependent Risk After Breast Cancer RT
Source: Medscape Hematology-Oncology Headlines [2014.04.14]
The risk of developing a primary lung cancer after radiotherapy for breast cancer increases in a dose-response manner, with these odds jumping 17-fold in smokers.
Medscape Medical News
Published Studies Related to Aromasin (Exemestane)
Bone density and structure in healthy postmenopausal women treated with
exemestane for the primary prevention of breast cancer: a nested substudy of the
MAP.3 randomised controlled trial. 
of potential widespread use, we examined the safety of exemestane on bone health... INTERPRETATION: 2 years of treatment with exemestane worsens age-related bone
Exemestane for breast-cancer prevention in postmenopausal women. [2011.06.23]
BACKGROUND: Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer... CONCLUSIONS: Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life. (Funded by Pfizer and others; NCIC CTG MAP.3 ClinicalTrials.gov number, NCT00083174.).
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. [2011.06.10]
PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations... CONCLUSION: Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demonstrated that the three agents tested are biologically equivalent and therefore likely to have similar adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be detected by post-treatment profiling.
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. [2011.04.20]
PURPOSE: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a prospectively planned pathology substudy testing the predictive value of progesterone receptor (PgR) expression for outcome of estrogen receptor-positive (ER-positive) early breast cancer treated with exemestane versus tamoxifen... CONCLUSION: Preferential exemestane versus tamoxifen treatment benefit was not predicted by PgR expression; conversely, patients with ER-rich tumors may derive additional benefit from exemestane. Quantitative analysis of ER and PgR expression provides highly significant information on risk of early relapse (within 1 to 3 years) during treatment.
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. [2011.04]
We hypothesized that exemestane (EXE) would reduce mammographic breast density and have unique effects on biomarkers of bone and lipid metabolism. Healthy postmenopausal women were randomized to EXE (25 mg daily) or placebo (PLAC) for 12 months and followed for a total of 24 months... Changes in lipid parameters on this trial were modest and reversible.
Clinical Trials Related to Aromasin (Exemestane)
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Active, not recruiting]
To compare recurrence free survival between two treatment groups (5 years with exemestane vs
2. 5 to 3 years tamoxifen followed by 2 to 2. 5 years of exemestane for a total duration of 5
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Terminated]
The purpose of this study is to find out if the two different formulations of exemestane
(Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and
pharmacokinetics, i. e., if ultimately both formulations have the same efficacy in
postmenopausal women with metastatic breast cancer who have failed previous antiestrogens
therapy and are equally safe.
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin [Recruiting]
To generate the following data from patients with early breast cancer treated with Aromasin®
in the adjuvant setting in India.
- Efficacy of the treatment with Aromasin®
- Safety of the treatment with Aromasin®
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients [Recruiting]
The purpose of this study is to assess the safety and effectiveness of AZD4547 in
combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1
polysomy (FISH4/5) or gene amplification (FISH 6)
Reports of Suspected Aromasin (Exemestane) Side Effects
Disease Progression (19),
Breast Cancer (18),
Abdominal Distension (12),
Bone Pain (11),
Headache (11), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 2 ratings/reviews, Aromasin has an overall score of 8.50. The effectiveness score is 9 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Aromasin review by 57 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Breast Cancer|
|Dosage & duration:|| || 5mg taken 1/day for the period of 3 years|
|Other conditions:|| || under-active thyroid|
|Other drugs taken:|| || Synthroid|
|Benefits:|| || Aromasin's treatment benefits are unknown. I have not had a reoccurance of breast cancer while on the drug, though unsure we can attribute that with the drug treatment itself. Perhaps there are other positive health-related items coming into play, such as exerciase and eating habits. Not aware of any side effects or adverse reactions. Drug is very expensive, however. |
|Side effects:|| || As mentioned above, I have not had any side effects from Aromasin other than hot flashes and night sweats. These may be due to menopause rather than the treatment itself. The hot flashes have been relatively mild and can be controlled, for the most part, by limiting or removing all alcoholic beverages. |
|Comments:|| || After breast cancer treatment of chemo. and radiation I was put on Tamoxifen for several years, about 5 years. After Tamoxifen, it was recommended that I start taking Aromasin, which I have done for about 3 years. My doctor said it is not known how long women should be on Aromasin and still receeve a benefit from taking the drug.|
Aromasin review by 58 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || eostrogen-positive breast cancer|
|Dosage & duration:|| || 25mg taken daily for the period of 4 years|
|Other conditions:|| || high blood pressure|
|Other drugs taken:|| || various blood pressure medications|
|Benefits:|| || During the 4 years so far [out of 5], I have had no recurrance of the tumour and no additional tumours have been detected by ultra-sound, mammogram, and twice-yearly check-ups. Perhaps the greatest benefit is the gradual reduction in stress experienced as a result of my on-going stabilised condition after a lumpectomy.|
|Side effects:|| || I had some initial swelling of my hip, knee and ankle joints in the morning which slowly subsided during the day. The medication also aggravated the hot-flushes of the menopause, making them initially frequent and copious, and on-going for the treatment duration so far - tho with reduced frequency now in Year 4. I also experience considerable thirst.|
|Comments:|| || I was put on Aromasin after 6 months on Tamoxifen because I suffered debilitating muscle cramps on Tamoxifen as well as joint problems and extreme hot flushes. Aromasin has been kinder, and so far I have taken it daily for 4 years out of an initial 5. It may be prescribed beyond 5 years, I'm not sure. It has relatively slight side effects now but in the first 6 months I was conscious of its effects on my body - not intolerable by any means, just noticable.|
Page last updated: 2014-04-18